Trial Profile
An Open-Label Phase 1b Study to Evaluate the Dose-Related Safety, Efficacy, and Pharmacokinetic Profile of Different Doses of QL-007 in Chronic Hepatitis B Patients
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Jun 2020
Price :
$35
*
At a glance
- Drugs QL-007 (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Qilu Pharmaceutical
- 18 Dec 2018 New trial record